ACIU
AC Immune Ltd
2.60$
+3.6%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.9% | 99.3% | 99.2% | 98.1% | 98.2% | 97.8% | 97.1% | 77.5% | 68.9% | 68.5% | 74.5% | 62.7% | |
| 10.9% | 95.7% | 97.5% | 94.2% | 79.6% | 64.7% | 67.4% | 31.4% | 17.0% | 42.9% | 15.7% | 17.4% | |
| 10.9% | 95.7% | 97.5% | 94.2% | 94.9% | 96.4% | 94.6% | 75.8% | 65.9% | 56.4% | 71.7% | 59.2% | |
| 85.8% | 0.4% | 0.9% | 2.8% | 2.1% | 0.5% | 0.7% | 0.4% | 0.2% | 8.2% | 0.5% | 0.9% | |
| 1.1% | 3.1% | 0.2% | -1.0% | 0.0% | -0.5% | -0.8% | -0.5% | 0.0% | -0.3% | – | – | |
| 1.8% | 0.6% | 0.7% | 1.8% | 1.7% | 2.1% | 2.8% | 3.1% | 3.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | 19.3% | 27.1% | 27.6% | 21.8% | 32.7% | |
| 22.5% | 11.1% | 8.8% | 11.5% | 9.6% | 9.0% | 9.7% | 11.3% | 9.1% | 12.1% | 51.4% | 70.9% | |
| 14.6% | 7.6% | 6.4% | 7.4% | 6.7% | 5.9% | 5.9% | 7.7% | 6.2% | 7.4% | 43.7% | 61.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.4% | 0.2% | 0.2% | 0.3% | 0.4% | 0.4% | 0.6% | |
| 5.2% | 2.2% | 2.6% | 0.8% | 1.0% | 0.0% | 0.9% | 0.8% | 0.5% | 0.9% | 1.2% | 1.3% | |
| 0.0% | 0.0% | 0.0% | 0.3% | 0.1% | 0.0% | – | – | – | – | – | – | |
| 77.5% | 88.9% | 91.2% | 88.5% | 90.4% | 91.0% | 90.3% | 88.7% | 90.9% | 87.9% | 48.6% | 29.1% | |
| -199.5% | -50.5% | -30.1% | -55.0% | -62.0% | -25.2% | -55.6% | -76.9% | -142.0% | -173.0% | -159.5% | -284.6% | |
| 182.8% | 69.3% | 32.1% | 43.4% | 31.5% | 23.8% | 30.1% | 28.7% | 44.9% | 46.3% | 43.2% | 65.2% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.